North American Blastomycosis Arthur C
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
WO 2014/134709 Al 12 September 2014 (12.09.2014) P O P C T
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2014/134709 Al 12 September 2014 (12.09.2014) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/05 (2006.01) A61P 31/02 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (21) International Application Number: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, PCT/CA20 14/000 174 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, 4 March 2014 (04.03.2014) KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (25) Filing Language: English OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (26) Publication Language: English SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (30) Priority Data: ZW. 13/790,91 1 8 March 2013 (08.03.2013) US (84) Designated States (unless otherwise indicated, for every (71) Applicant: LABORATOIRE M2 [CA/CA]; 4005-A, rue kind of regional protection available): ARIPO (BW, GH, de la Garlock, Sherbrooke, Quebec J1L 1W9 (CA). GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (72) Inventors: LEMIRE, Gaetan; 6505, rue de la fougere, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, Sherbrooke, Quebec JIN 3W3 (CA). -
Antifungals, Topical
Therapeutic Class Overview Antifungals, Topical INTRODUCTION The topical antifungals are available in multiple dosage forms and are indicated for a number of fungal infections and related conditions. In general, these agents are Food and Drug Administration (FDA)-approved for the treatment of cutaneous candidiasis, onychomycosis, seborrheic dermatitis, tinea corporis, tinea cruris, tinea pedis, and tinea versicolor (Clinical Pharmacology 2018). The antifungals may be further classified into the following categories based upon their chemical structures: allylamines (naftifine, terbinafine [only available over the counter (OTC)]), azoles (clotrimazole, econazole, efinaconazole, ketoconazole, luliconazole, miconazole, oxiconazole, sertaconazole, sulconazole), benzylamines (butenafine), hydroxypyridones (ciclopirox), oxaborole (tavaborole), polyenes (nystatin), thiocarbamates (tolnaftate [no FDA-approved formulations]), and miscellaneous (undecylenic acid [no FDA-approved formulations]) (Micromedex 2018). The topical antifungals are available as single entity and/or combination products. Two combination products, nystatin/triamcinolone and Lotrisone (clotrimazole/betamethasone), contain an antifungal and a corticosteroid preparation. The corticosteroid helps to decrease inflammation and indirectly hasten healing time. The other combination product, Vusion (miconazole/zinc oxide/white petrolatum), contains an antifungal and zinc oxide. Zinc oxide acts as a skin protectant and mild astringent with weak antiseptic properties and helps to -
Epidemiology and Geographic Distribution of Blastomycosis, Histoplasmosis, and Coccidioidomycosis, Ontario, Canada, 1990–2015 Elizabeth M
Epidemiology and Geographic Distribution of Blastomycosis, Histoplasmosis, and Coccidioidomycosis, Ontario, Canada, 1990–2015 Elizabeth M. Brown,1 Lisa R. McTaggart,1 Deirdre Dunn, Elizabeth Pszczolko, Kar George Tsui, Shaun K. Morris, Derek Stephens, Julianne V. Kus,2 Susan E. Richardson2 In support of improving patient care, this activity has been planned and implemented by Medscape, LLC and Emerging Infectious Diseases. Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Medscape, LLC designates this Journal-based CME activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. All other clinicians completing this activity will be issued a certificate of participation. To participate in this journal CME activity: (1) review the learning objectives and author disclosures; (2) study the education content; (3) take the post-test with a 75% minimum passing score and complete the evaluation at http://www.medscape.org/journal/eid; and (4) view/print certificate. For CME questions, see page 1400. Release date: June 15, 2018; Expiration date: June 15, 2019 Learning Objectives Upon completion of this activity, participants will be able to: • Describe the epidemiology and geographic distribution of microbiology laboratory-confirmed -
Therapeutic Class Overview Antifungals, Topical
Therapeutic Class Overview Antifungals, Topical INTRODUCTION The topical antifungals are available in multiple dosage forms and are indicated for a number of fungal infections and related conditions. In general, these agents are Food and Drug Administration (FDA)-approved for the treatment of cutaneous candidiasis, onychomycosis, seborrheic dermatitis, tinea corporis, tinea cruris, tinea pedis, and tinea versicolor (Clinical Pharmacology 2018). The antifungals may be further classified into the following categories based upon their chemical structures: allylamines (naftifine, terbinafine [only available over the counter (OTC)]), azoles (clotrimazole, econazole, efinaconazole, ketoconazole, luliconazole, miconazole, oxiconazole, sertaconazole, sulconazole), benzylamines (butenafine), hydroxypyridones (ciclopirox), oxaborole (tavaborole), polyenes (nystatin), thiocarbamates (tolnaftate [no FDA-approved formulations]), and miscellaneous (undecylenic acid [no FDA-approved formulations]) (Micromedex 2018). The topical antifungals are available as single entity and/or combination products. Two combination products, nystatin/triamcinolone and Lotrisone (clotrimazole/betamethasone), contain an antifungal and a corticosteroid preparation. The corticosteroid helps to decrease inflammation and indirectly hasten healing time. The other combination product, Vusion (miconazole/zinc oxide/white petrolatum), contains an antifungal and zinc oxide. Zinc oxide acts as a skin protectant and mild astringent with weak antiseptic properties and helps to -
Blastomycosis — Wisconsin, 1986–1995
July 19, 1996 / Vol. 45 / No. 28 601 Blastomycosis — Wisconsin 603 Measles Pneumonitis Following Measles-Mumps-Rubella Vaccination of a Patient with HIV Infection, 1993 606 Biopsy-Confirmed Hypersensitivity Pneumonitis in Automobile Production Workers Exposed to Metalworking Fluids — Michigan 611 Update: Outbreaks of Cyclospora cayetanensis Infection — United States and Canada, 1996 Blastomycosis — Wisconsin, 1986–1995 Blastomycosis is— a Conti diseasenued of humans and animals caused by inhalation of airborne spores from Blastomyces dermatitidis, a dimorphic fungus found in soil. The spec- trum of clinical manifestations of blastomycosis includes acute pulmonary disease, subacute and chronic pulmonary disease (most common presentations), and dissemi- nated extrapulmonary disease (cutaneous manifestations are most common, fol- lowed by involvement of the bone, the genitourinary tract, and central nervous system) (1 ). Although the disease is not nationally notifiable, it was designated a re- portable condition in Wisconsin in 1984 following two large outbreaks. This report summarizes information about cases of blastomycosis reported in Wisconsin during 1986–1995 and highlights the importance of surveillance for blastomycosis in areas with endemic disease. In Wisconsin, cases of blastomycosis are reported to the Division of Health (DOH), Wisconsin Department of Health and Social Services. A confirmed case is defined as isolation of B. dermatitidis or visualization of characteristic broad-based budding yeast from a clinical specimen obtained from a person with clinically compatible ill- ness (e.g., subacute pneumonia or characteristic skin lesions). During 1986–1995, a total of 670 cases of blastomycosis were reported to DOH, representing a statewide mean annual incidence rate of 1.4 cases per 100,000 persons. -
Below Chart Lists Over-The-Counter (OTC) Medicines Considered Low Risk for Pregnant Women When Taken for the Occasional Mild Illness
Below chart lists over-the-counter (OTC) medicines considered low risk for pregnant women when taken for the occasional mild illness. It also mentions a few that are not safe. A few brand names are listed as examples, but there are many more on the market. Of course, nothing is 100 percent safe for all women, so it's a good idea to check with your doctor before taking any kind of medicine during pregnancy – even an over-the-counter product. Don't take more than the recommended dose and, if possible, avoid taking anything during your first trimester, when your developing baby is most vulnerable. NOTE: If you have a question about the safety of any medication during pregnancy, visit the Organization of Teratology Information Specialists Web site. There you'll find fact sheets on various drugs and exposures that can affect your baby as well as a list of teratogen information services that you can contact. Problem Safe to take Heartburn, gas and Antacids for heartburn (Maalox, Mylanta, Rolaids, Tums) bloating, upset stomach Simethicone for gas pains (Gas-X, Maalox Anti-Gas, Mylanta Gas, Mylicon) Cough or cold Guaifenesin, an expectorant (Hytuss, Mucinex, Naldecon Senior EX, Robitussin) Dextromethorphan, a cough suppressant (Benylin Adult, Robitussin Maximum Strength Cough, Scot-Tussin DM, Vicks 44 Cough Relief) Guaifenesin plus dextromethorphan (Benylin Expectorant, Robitussin DM, Vicks 44E) Cough drops Vicks VapoRub Not safe to take: Cold remedies that contain alcohol The decongestants pseudoephedrine and phenylephrine, which can affect blood -
Practical Dermatology Methodical Recommendations
Vitebsk State Medical University Practical Dermatology Methodical recommendations Adaskevich UP, Valles - Kazlouskaya VV, Katina MA VSMU Publishing 2006 616.5 удк-б-1^«адл»-2о -6Sl«Sr83p3»+4£*łp30 А28 Reviewers: professor Myadeletz OD, head of the department of histology, cytology and embryology in VSMU: professor Upatov Gl, head of the department of internal diseases in VSMU Adaskevich IIP, Valles-Kazlouskaya VV, Katina МЛ. A28 Practical dermatology: methodical recommendations / Adaskevich UP, Valles-Kazlouskaya VV, Katina MA. - Vitebsk: VSMU, 2006,- 135 p. Methodical recommendations “Practical dermatology” were designed for the international students and based on the typical program in dermatology. Recommendations include tests, clinical tasks and practical skills in dermatology that arc used as during practical classes as at the examination. УДК 616.5:37.022.=20 ББК 55.83p30+55.81 p30 C Adaskev ich UP, Valles-Ka/.louskaya VV, Katina MA. 2006 OVitebsk State Medical University. 2006 Content 1. Practical skills.......................................................................................................5 > 1.1. Observation of the patient's skin (scheme of the case history).........................5 1.2. The determination of skin moislness, greasiness, dryness and turgor.......... 12 1.3. Dermographism determination.........................................................................12 1.4. A method of the arrangement of dropping and compressive allergic skin tests and their interpretation........................................................................................................ -
Ascosphaerales)
INIII;ITION OFC1[ALKBROOD SPORE GERMINATIONIN VITRO (Ascosp haera aggrega ta: Ascosphaerales) Station Bulletin 656 January 1982 Agricultural Fxperiment Station Oreg' State University, Corvallis ¶ INHIBITION OF CHALKBROOD SPORE GERMINATION IN VITRO (Ascosphaera aggregata: Ascosphaerales.) W. P. Stephen, J.D. Vandenberg, B. L. Fichter, and G. Lahm Authors: Professor, research assistants and technician in theDepartment of Entomology, Oregon State University. ABSTRACT Sixty-five compounds, including general microbicides, fungicides, antibiotics, and fumigants were screened for their sporicidal effect on Ascosphaera aggregata. The chalkbrood spore, the only readily accessible stage of the fungus, was unaffected by most of the materials tested. Only the halogenated general microbicides, iodine, hypochiorite, and stabilized dry chlorine, demonstrated consistent sporicidal activity at low concen- trations. Suggestions are made as to possible disease control strategies. ACKNOWLEDGMENTS The Multistate Chalkbrood Project is supported by contributions from grower groups and industry representatives in Idaho, Nevada, Oregon, and Washington; the Idaho, Nevada, and Washington Alfalfa Seed Commissions; Universities of Idaho and Nevada-Reno; Oregon and Washington State Universities, and by a cooperative agreement with the USDA/SEA Federal Bee Laboratory, Logan, Utah. The authors thank Dr. J. Corner and Mr. D. McCutcheon, British Columbia Ministry of Agriculture and Food, Vernon and Surrey, B.C., for help with the ETO tests; Dr. G. Puritch, Canadian Forestry Service, Pacific Forest Research Center, Victoria, B.C., for supplying the fatty acid derivatives; and Dr. D. Coyier, IJSDA/SEA/AR Ornamental Plants Laboratory, Corvallis, Ore., for assistance with fumigation studies. 1 INTRODUCTION Ascosphaera aggregata Skou is the causative agent ofchalkbrood in larvae of the alfalfa leafcutting bee, Megachilerotundata (Fabricius) (Vandenberg and Stephen, 1982). -
| Oa Tai Ei Rama Telut Literatur
|OA TAI EI US009750245B2RAMA TELUT LITERATUR (12 ) United States Patent ( 10 ) Patent No. : US 9 ,750 ,245 B2 Lemire et al. ( 45 ) Date of Patent : Sep . 5 , 2017 ( 54 ) TOPICAL USE OF AN ANTIMICROBIAL 2003 /0225003 A1 * 12 / 2003 Ninkov . .. .. 514 / 23 FORMULATION 2009 /0258098 A 10 /2009 Rolling et al. 2009 /0269394 Al 10 /2009 Baker, Jr . et al . 2010 / 0034907 A1 * 2 / 2010 Daigle et al. 424 / 736 (71 ) Applicant : Laboratoire M2, Sherbrooke (CA ) 2010 /0137451 A1 * 6 / 2010 DeMarco et al. .. .. .. 514 / 705 2010 /0272818 Al 10 /2010 Franklin et al . (72 ) Inventors : Gaetan Lemire , Sherbrooke (CA ) ; 2011 / 0206790 AL 8 / 2011 Weiss Ulysse Desranleau Dandurand , 2011 /0223114 AL 9 / 2011 Chakrabortty et al . Sherbrooke (CA ) ; Sylvain Quessy , 2013 /0034618 A1 * 2 / 2013 Swenholt . .. .. 424 /665 Ste - Anne -de - Sorel (CA ) ; Ann Letellier , Massueville (CA ) FOREIGN PATENT DOCUMENTS ( 73 ) Assignee : LABORATOIRE M2, Sherbrooke, AU 2009235913 10 /2009 CA 2567333 12 / 2005 Quebec (CA ) EP 1178736 * 2 / 2004 A23K 1 / 16 WO WO0069277 11 /2000 ( * ) Notice : Subject to any disclaimer, the term of this WO WO 2009132343 10 / 2009 patent is extended or adjusted under 35 WO WO 2010010320 1 / 2010 U . S . C . 154 ( b ) by 37 days . (21 ) Appl. No. : 13 /790 ,911 OTHER PUBLICATIONS Definition of “ Subject ,” Oxford Dictionary - American English , (22 ) Filed : Mar. 8 , 2013 Accessed Dec . 6 , 2013 , pp . 1 - 2 . * Inouye et al , “ Combined Effect of Heat , Essential Oils and Salt on (65 ) Prior Publication Data the Fungicidal Activity against Trichophyton mentagrophytes in US 2014 /0256826 A1 Sep . 11, 2014 Foot Bath ,” Jpn . -
Health Service
UNIVERSITY OF ILLINOIS HEALTH SERVICE Departments in Urbana-Champajgn Thirty,third Annual Report 1948-1949 J. How AID BEARD, M. D. University Health Officer Urbana, Illinois I have the honor to present herewith this report as edited and prepared by the late Dr. J. Howard Beard. 1'h* pr1ntinc and binding have been completed with., IUper- vision. TABLE OF CONTENTS Pall" FORE":1ORD 1 SERVICES 2 I. University Students 2 II. University High School Studente 2 III. Re t irc~9nt System 2 IV. Employees 6 V. Student and Private Pilots 7 VI. Foodhandler s 7 VII. Applicants for l-!arriage Certificates 7 VIII. Laboratory SerTice 7 9 I! General 9 II. Albuminuria 10 Ill. Hear ~ ~lBeaBe 10 IV. Tube~culosio 10 V. Mental Hygiene 11 VI. Oral Hygiene 12 COi>iM1Jl!ICABLE DISEASE 1) I. Students 1) II. Faculty and Civ!l SerTice Employees 14 VACCII'.ATIONS AJID UilltJllIZATIONS 14 COOPllRATION WITH CT!mR DEPARTMElITS 14 I. Military Classification 14 II. ~hysical Education Classification 14 INSTRUCTION IN I!YG IENE 15 I. Proficiency Examination 16 II. Hygiene 102 and 105, Elementary Hygiene and Sanitation 16 III. Hygiene 110, For Coachee and Teacheru 17 IV. nr6~ene 216, Por Occupational Therapy Student. 17 V. Hygiene X-103, Extension Course 17 VI. Hygiene X-225, Extension Course 17 SAl!ITATIOli 17 FIRST AID CABINETS 18 SPBCIAL SERV I C~ AT UN IVERSITY FJVbh~S 18 S TA~ !.ABORATORT Sz:RVICE 18 :uJqtm5TS FOR I NFCmiAT ION 19 TlrE GllNERAL PRACTITIONER AND '!'HE I!EA1TH SERVIClil 19 HOSPl TALlZATIOl1 19 I. McKinley Hospital 20 II. -
Antifungal Drugs
Antifungal Drugs Antifungal or antimycotic drugs are those agents used to treat diseases caused by fungus. Fungicides are drugs which destroy fungus and fungistatic drugs are those which prevent growth and multiplication of fungi. Collectively these drugs are often referred to as antimycotic or antifungal drugs. General characteristics of fungus: Fungi of medical significance are of two groups: Yeast Unicellular (Candida, Crytococcus) Molds Multicellular; filamentous consist of hyphae (Aspergillus, Microsporum, Trichophyton) They are eukaryotic i.e. they have well defined nucleus and other nuclear materials. They are made of thin threads called hyphae. The hyphae have a cell wall (like plant cells) made of a material called chitin. The hyphae are often multinucleate. They do not have chlorophyll, can’t make own food by photosynthesis, therefore derive nutrients by means of saprophytic or parasitic existence. Cell membrane is made up of ergosterol. Types of fungal infections: Fungal infections are termed as mycoses and in general can be divided into: Superficial infections: Affecting skin, nails, scalp or mucous membranes; e.g. Tinea versicolor Dermatophytosis: Fungi that affect keratin layer of skin, hair and nail; e.g. Tinea pedis, rign worm infection. Candidiasis: Yeast infections caused by (Malassezia pachydermatis), oral thrush (oral candidiasis), vulvo-vaginitis, nail infection. Systemic/Deep infections: Affecting deeper tissues and organ they usually affect lungs, heart and brain leading to pneumonia, endocarditis and meningitis. Systemic infections are associated with immunocompromised patients, these diseases are serious and often life threatening due to the organ involved. Some of the serious systemic fungal infections in man are candidiasis, cryptococcal meningitis, pulmonary aspergillosis. -
Blastomycosis Information for Dog Owners
Blastomycosis Information for Dog Owners Key Facts Disease in dogs can be: • Nonspecific - dogs may have fever, weight loss, or lack of appetite. • Associated with signs in a specific organ/system, such as: • Respiratory disease, e.g. cough, difficulty breathing. • Eye disease, e.g. blindness, swelling within or around the eye. • Skin, e.g. ulcerations or mass-like lesions on the face, nose or nails. • Bone, e.g. lameness or swelling. If appropriate treatment is started early, most dogs can be cured. However, long- term expensive treatment may be required. Dogs living in or traveling to specific locations (see below) have the highest exposure to the disease-causing mold and are at greatest risk. Dogs involved in hunting or field trials in these areas are at increased risk of disease. What is it? Blastomycosis is due to infection with the fungus Blastomyces dermatitidis. The fungus is found in the environment, most often in sandy soil near bodies of water. Disease in dogs can vary with infection site; lethargy, fever, cough and trouble breathing are most common. Where is it? Due to the preferred environmental conditions of the fungus, blastomycosis is generally found in specific regions of North America. Although there is some risk of blastomycosis to dogs outside of these regions, it is very unusual to see dogs with blastomycosis who have not lived in (or traveled to) the following high-risk regions: • USA: Ohio River Valley (i.e. Ohio, Indiana, Blastomyces dermatitidis fungus in canine liver tissue Kentucky, southwest Pennsylvania, northwest under microscopic examination (Public Domain: Centers for West Virginia), Mississippi, Missouri and the Disease Control and Prevention) Mid-Atlantic States.